News Valerio Therapeutics

Stocks

ALVIO

FR0010095596

Pharmaceuticals

Real-time Euronext Paris 07:05:14 2026-10-21 EDT			5-day change	1st Jan Change
0.4250 ^EUR	+3.41%		+4.17%	+207.97%

10-12	Valerio Therapeutics Finalizes Purchase of Etherna Immunotherapies	MT
10-07	Valerio Therapeutics Société anonyme completed the acquisition of eTheRNA immunotherapies NV.	CI

All News

Mentions Relevance

10-12	Valerio Therapeutics Finalizes Purchase of Etherna Immunotherapies	MT
10-12	Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic	BU
10-07	Valerio Therapeutics Société anonyme completed the acquisition of eTheRNA immunotherapies NV.	CI
10-07	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2026	CI
10-07	Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026	BU
10-07	Valerio Therapeutics : provides an update on its business and presents its financial results for the first half of 2026	PU
08-24	Valerio Therapeutics to Buy Etherna Immunotherapies in EUR30 Million Deal	MT
08-24	Valerio Therapeutics : Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors	PU
08-24	Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors	BU
08-17	Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase	MT
08-17	Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition	BU
07-16	Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update	BU
07-16	Valerio Therapeutics : Announces Development Collaboration with Abivax and Provides Pipeline Update	PU
07-01	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines	BU
07-01	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines	PU
06-30	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million. Valerio Therapeutics Société anonyme entered into a definitive share purchase agreement to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.	CI
06-17	Valerio Therapeutics Appoints New Chief Executive Officer
06-17	Valerio Therapeutics Names New CEO	MT
06-16	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	BU
06-16	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes	CI
06-16	Valerio Therapeutics Société Anonyme Announces CEO Changes	CI
06-16	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting	PU
05-19	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration	MT
05-18	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co	RE
05-18	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company	BU